Volume 26, Number 8—August 2020
Research
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Manish Patel
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
Table 2
Immunosuppressive agents used in analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States
| Agent |
|---|
| Chemotherapeutic |
| Aldesleukin |
| Alemtuzumab |
| Altretamine |
| Amifostine |
| Arsenic trioxide |
| Asparaginase |
| Azacitidine |
| Bendamustine hydrochloride |
| Bevacizumab |
| Bexarotene |
| Bortezomib |
| Brentuximab vedotin |
| Busulfan |
| Cabazitaxel |
| Capecitabine |
| Carboplatin |
| Carfilzomib |
| Carmustine |
| Cetuximab |
| Chlorambucil |
| Cisplatin |
| Cladribine |
| Clofarabine |
| Cyclophosphamide |
| Dacarbazine |
| Dactinomycin |
| Dasatinib |
| Daunorubicin citrate liposome |
| Decitabine |
| Denileukin diftitox |
| Docetaxel |
| Etoposide |
| Everolimus |
| Floxuridine |
| Fluorouracil |
| Gefitinib |
| Ifosfamide |
| Ipilimumab |
| Ixabepilone |
| Lomustine |
| Melphalan |
| Mercaptopurine |
| Mesna |
| Methotrexate |
| Mitomycin |
| Mitotane |
| Nelarabine |
| Ofatumumab |
| Oxaliplatin |
| Paclitaxel |
| Panitumumab |
| Pegaspargase |
| Pemetrexed |
| Pentostatin |
| Pertuzumab |
| Plicamycin |
| Pralatrexate |
| Rituximab |
| Romidepsin |
| Streptozocin |
| Temozolomide |
| Teniposide |
| Thioguanine |
| Thiotepa |
| Trastuzumab |
| Tretinoin |
| Vorinostat |
| Immune-modulating |
| Abatacept |
| Adalimumab |
| Alefacept |
| Anakinra |
| Auranofin |
| Aurothioglucose |
| Azathioprine |
| Basiliximab |
| Belatacept |
| Belimumab |
| Certolizumab pegol |
| Cyclosporine |
| Daclizumab |
| Denosumab |
| Eculizumab |
| Efalizumab |
| Etanercept |
| Gold sodium thiomalate |
| Golimumab |
| Infliximab |
| Interferon alfacon-1 |
| Leflunomide |
| Lenalidomide |
| Mycophenolate mofetil |
| Natalizumab |
| Palifermin |
| Palivizumab |
| Pegademase bovine |
| Pimecrolimus |
| Sirolimus |
| Tacrolimus |
| Thalidomide |
| Tocilizumab |
| Ustekinumab |
| Systemic corticosteroids |
| Dexamethasone |
| Methylprednisolone |
| Prednisolone |
| Prednisone |
Page created: April 29, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.